Redx announced the appointment of Dr. James Mead as new full time Chief Financial Officer (CFO) and an Executive Director of the Board, effective 1 February 2019. He takes over from Dominic Jackson who has served as interim Chief Financial Officer and Executive Director of the Board since 3 November 2017 and who will step down at the end of January 2019. James is an experienced finance professional in the sector, having held a variety of senior roles over a 16-year career at AstraZeneca, including Chief Financial Officer of AstraZeneca Netherlands, Finance Director for multiple clinical development project teams and Director of Investor Relations.
Redx Pharma Plc London S.E.
Equities
REDX
GB00BSNB6S51
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15 GBX | +31.58% | -.--% | -31.82% |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- 0RX Stock
- REDX Stock
- News Redx Pharma Plc
- Redx Pharma Plc Announces Management Changes